Abstracts tagged "Systemic sclerosis"

Abstract Number: 0653 • ACR Convergence 2023
Association Between Systemic Sclerosis and Increased Risk of Ischemic Stroke: A Meta-Analysis
Christina Flourou¹, Andreas Liampas¹ and Konstantinos Parperis², ¹Nicosia General Hospital, Nicosia, Cyprus, ²University of Cyprus Medical School, Nicosia, Cyprus
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune rheumatic disease characterized by significant vascular abnormalities due to microvascular damage and intimal proliferation in the small arterioles.…
Abstract Number: 0787 • ACR Convergence 2023
Understanding Distinct Resident and Migratory Fibroblast Populations in Systemic Sclerosis Skin Through Single-cell RNAseq and Immunohistochemistry
Kristina Clark¹, Shiwen Xu², Voon Ong³, Christopher Buckley⁴ and Christopher Denton², ¹Barts Health NHS Trust, London, United Kingdom, ²University College London, London, United Kingdom, ³UCL Medical School Royal Free Campus, London, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: We previously described distinct migratory and resident fibroblast populations from lesional skin biopsies in SSc patients. Both populations are profibrotic compared with those from…
Abstract Number: 0948 • ACR Convergence 2023
Nintedanib Alters Fibroblast and Macrophage Diversity in a 3D Skin Model of Systemic Sclerosis (SSc)
Noelle Kosarek¹, Tamar Abel², Sasha Shenk³, Tammara Wood², Jonathan Garlick⁴, Patricia Pioli⁵ and Michael Whitfield⁵, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth College, Hanover, NH, ³Tufts University, Boston, MA, ⁴Tufts University School of Dental Medicine, Boston, MA, ⁵Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs. While the tyrosine kinase inhibitor Nintedanib is…
Abstract Number: 1515 • ACR Convergence 2023
Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis
Dinesh Khanna¹, Christopher Denton², Masataka Kuwana³, Daniel Furst⁴, Suiyuan Huang¹, Barbara White⁵ and Robert Spiera⁶, ¹University of Michigan, Ann Arbor, MI, ²University College London, London, United Kingdom, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴University of California Los Angeles, Los Angeles, CA, ⁵SFJ Pharmaceuticals, Towson, MD, ⁶Hosptial for Special Surgery, New York, NY
Background/Purpose: Revised CRISS has been proposed an approvable outcome measure in early diffuse cutaneous SSc (dcSSc)1. The index is undergoing the FDA review as part…
Abstract Number: 1668 • ACR Convergence 2023
Cell Specific Molecular Profiling of Scleroderma Associated Interstitial Lung Disease Subtypes
Monica Yang¹, Fred Deiter¹, Emily Flynn¹, Jessica Neely¹, Seoyeon Lee², John Greenland¹, Marina Sirota³ and Paul Wolters¹, ¹University of California San Francisco, San Francisco, CA, ²Yale University School of Medicine, New Haven, CT, ³Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA
Background/Purpose: Interstitial lung disease (ILD) is present in up to 90% of patients with systemic sclerosis (SSc) and the leading cause of SSc-related mortality. SSc-ILD…
Abstract Number: 2361 • ACR Convergence 2023
Optimal Combination of Circulating Biomarkers for Predicting the Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis
Keina Yomono¹, Dinesh Khanna² and Masataka Kuwana³, ¹Nippon Medical School University, Tokyo, Japan, ²University of Michigan, Ann Arbor, MI, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: In patients with systemic sclerosis (SSc), progression of interstitial lung disease (ILD) is associated with an increased mortality. Since the course of SSc-ILD is…
Abstract Number: 0614 • ACR Convergence 2023
Self-Reported Sexual Dysfunction and Perceptions of Rheumatologist Engagement on This Issue in Patients with Systemic Sclerosis
Liza Morales¹, Robert Spiera², Jessica Gordon¹, Deanna Jannat-Khah¹ and Kimberly Lakin¹, ¹Hospital for Special Surgery, New York, NY, ²Hosptial for Special Surgery, New York, NY
Background/Purpose: Few studies have investigated the prevalence and risk factors of sexual dysfunction among individuals with systemic sclerosis (SSc). The purpose of this study is…
Abstract Number: 0632 • ACR Convergence 2023
A Longitudinal Analysis of Mouth Opening in 1101 Systemic Sclerosis Patients from the French National Cohort Study
Benjamin Chaigne¹, Alexandre Bense², Christian AGARD³, Yannick ALLANORE⁴, Gregory Pugnet⁵, Eric Hachulla⁶, Jérôme Avouac⁷, Boris Bienvenu⁸, Sylvain Palat⁹, Claire Grange¹⁰, Sabine Berthier¹¹, Emmanuel Chatelus¹², sebastien riviere¹¹, Marie-Elise Truchetet¹³, Jean-Emmanuel Kahn¹⁴, Francois Maurier¹⁵, elisabeth diot¹⁶, Alice Berezne¹¹ and Luc Mouthon¹⁷, ¹Paris Cité University, Paris, France, ²APHP, Paris, France, ³Internal medicine, Nantes University Hospital, Nantes, France, ⁴Université Paris Cité, Paris, France, ⁵CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ⁶University of Lille, Lille, France, ⁷Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France, ⁸Saint Joseph Hospital, Marseille, France, ⁹...., Paris, France, ¹⁰..., Paris, France, ¹¹Internal Medicine - Cochin University Hospital, Paris, France, ¹²Internal Medicine - Cochin University Hospital, Strasbourg, France, ¹³Bordeaux University Hospital, Bordeaux, France, ¹⁴AP-HP, Suresnes Cedex, France, ¹⁵Hôpitaux privés de Metz, Vaux / Frankreich, France, ¹⁶Internal Medicine - Cochin University Hospital, Tours, France, ¹⁷Hopital Cochin - Paris University, Paris, France
Background/Purpose: Few studies have evaluated mouth opening (MO) in systemic sclerosis (SSc). None have studied MO trajectories.Methods: We performed a multicentre study patients enrolled in…
Abstract Number: 0655 • ACR Convergence 2023
A Novel Association Between Lipodermatosclerosis and Key Vascular Outcomes in Systemic Sclerosis
Srijana Davuluri¹, Puneet Kapoor², Swarna Nandyala², David Fiorentino³, Julia Simard⁴ and Lorinda Chung⁵, ¹Stanford University- School of Medicine, Sunnyvale, CA, ²Stanford University- School of Medicine, Palo Alto, CA, ³Department of Dermatology, Stanford University, Redwood City, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA
Background/Purpose: Lipodermatosclerosis (LDS) is a progressive manifestation of chronic venous insufficiency characterized by distinctive lower extremity changes, including an "inverted champagne bottle" appearance, skin hyperpigmentation,…
Abstract Number: 0788 • ACR Convergence 2023
Whole Exome Sequencing and Evolutionary Action Missense Mutation Analysis Identifies MICB as a New SSc Susceptibility Locus and the Interferon Pathway as Contributors to SSc Pathogenesis
Shamika Ketkar¹, Hongzheng Dai¹, Brian Dawson¹, Lindsay Burrage¹, David Murdock¹, Jennifer Asmussen¹, Kevin Wilhelm¹, Olivier Lichtarge¹, Martin Kerick², Javier Martin³, Shervin Assassi⁴, Brendan Lee¹ and Maureen Mayes⁵, ¹Baylor College of Medicine, Houston, TX, ²Spanish National Research Council, Granada, Spain, ³Instituto de Parasitologia y Biomedicina Lopez-Neyra - CSIC, Granada, Spain, ⁴University of Texas McGovern Medical School at Houston, Houston, TX, ⁵Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Systemic Sclerosis (SSc) is characterized by fibrosis of the skin and internal organs associated with vasculopathy and autoantibodies and exhibiting wide clinical heterogeneity. Contributors…
Abstract Number: 0949 • ACR Convergence 2023
Development of Interstitial Pneumonia with Autoimmune Features in Conditional Tgfb3 Deletion
Toshihiko Komai¹, Tomohisa Okamura², Masanori Kono¹, Kazuhiko Yamamoto³ and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Background/Purpose: We found that TGF-β3 regulates humoral immunity in a context-dependent manner [1]. Recent genome-wide association study reveals that TGF-β3 might be a novel target…
Abstract Number: 1517 • ACR Convergence 2023
Comparing Deep Neural Network to Modified Rodnan Skin Score in a Trial for Belumosudil in Systemic Sclerosis Patients
Baran Gunes¹, Lucy Duran Camacho¹, Shawn Cowper², Gauri Panse², Elizabeth Bundschuh³, Alyssa Williams⁴, Nicolas Page⁵, Mary Karns⁶, Kathleen Aren⁶, Niki Pradhan⁷, Elana Bernstein⁸, Sarah Fantus⁹, Elizabeth Volkmann¹⁰, Heather Bukiri¹⁰, Chase Correia¹¹, Francis Wilson¹, Seamus Mawe¹², J. Matthew Mahoney¹³, Monique Hinchcliff¹⁴ and Rui Wang¹⁵, ¹Yale University School of Medicine, New Haven, CT, ²Yale School of Medicine - Dermatopathology, New Haven, CT, ³Yale University School of Medicine, New York, NY, ⁴Yale University School of Medicine, Winchester, MA, ⁵Yale University School of Medicine, Salem, CT, ⁶Northwestern University Division of Rheumatology, Chicago, IL, ⁷Columbia University Irving Medical Center, New York, NY, ⁸Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ⁹Kansas City Physician Partners- Center for Rheumatic Disease, Kansas City, MO, ¹⁰University of California Los Angeles, Los Angeles, CA, ¹¹Riverside Medical Group, Hampton, VA, ¹²The Jackson Laboratory, Bar Harbor, ME, ¹³Jackson Laboratory, Bar Harbor, ME, ¹⁴Yale School of Medicine, Westport, CT, ¹⁵Sanofi, Cambridge, MA
Background/Purpose: We previously published a proof-of-principle study demonstrating the potential utility of computer vision (Deep Neural Network/DNN) methods applied to stained skin biopsy sections from…
Abstract Number: 1699 • ACR Convergence 2023
Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis
Cosimo Bruni¹, Havard Fretheim², Lorenzo Tofani³, Yannick Weber¹, Eric Hachulla⁴, Patricia Carreira⁵, Dilia Giuggioli⁶, Paolo Airò⁷, Elise Siegert⁸, Ulf Müller-Ladner⁹, marco Matucci Cerinic¹⁰, Gabriela Riemekasten¹¹, Carmen Pilar Simeon-Aznar¹², Jeska de Vries-Bouwstra¹³, Lesley Ann Saketkoo¹⁴, Joerg Distler¹⁵, Alexandra Balbir-Gurman¹⁶, Ivan Castellvi¹⁷, Elisabetta Zanatta¹⁸, Vanessa Smith¹⁹, Christopher Denton²⁰, Britta Maurer²¹, Alessandro Giollo¹⁸, Florenzo Iannone²², Lorenzo Dagna²³, Marie-Elise Truchetet²⁴, Masataka Kuwana²⁵, Yannick ALLANORE²⁶, Yoshiya Tanaka²⁷, Mickael Martin²⁸, Edoardo Rosato²⁹, Ana Maria Gheorghiu³⁰, Francesco Del Galdo³¹, Kamal Solanki³², Alessandra Vacca³³, CATARINA RESENDE³⁴, SUSANA VIEIRA³⁵, Laszlo Czirjak³⁶, Marko Barisic³⁷, Francesco Paolo Cantatore³⁸, valeria Riccieri³⁹, Kristofer Andréasson⁴⁰, Lorinda Chung⁴¹, Carolina Muller⁴², Daniela OPRIS-BELINSKI⁴³, Simona Rednic⁴⁴, Petros Sfikakis⁴⁵, Yair Levy⁴⁶, Anna Maria Hoffmann-Vold⁴⁷, Oliver Distler¹, Vivien Hsu⁴⁸, Stefan Heitmann⁴⁹, Gianluca Moroncini⁵⁰, Michele Iudici⁵¹, Joerg Henes⁵², Ellen De Langhe⁵³, Ariane Herrick⁵⁴ and Carlomaurizio Montecucco⁵⁵, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Oslo University Hospital, Oslo, Norway, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴University of Lille, Lille, France, ⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, ⁷Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ⁸Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁹Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ¹⁰Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹¹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹²Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, ¹³Leiden University Medical Center, Leiden, Netherlands, ¹⁴University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹⁵Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ¹⁶Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁷Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ¹⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰University College London, London, United Kingdom, ²¹University Hospital Bern, University Bern, Bern, Switzerland, ²²Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ²³Ospedale San Raffaele, Milano, Italy, ²⁴Bordeaux University Hospital, Bordeaux, France, ²⁵Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁶Université Paris Cité, Paris, France, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, ²⁹Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, ³⁰Department of Internal Medicine and Rheumatology, Ion Cantacuzino Clinical Hospital, Bucharest, Romania, ³¹University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ³²Department of Rheumatology, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand, ³³II Chair of Rheumatology, University of Cagliari-Policlinico Universitario, Monserrato, Italy, ³⁴Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Lisboa, Portugal, ³⁵Hospital Fernando Fonseca, Lisbon, Portugal, ³⁶Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, ³⁷Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia, ³⁸Rheumatology Clinic – Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, ³⁹Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy, ⁴⁰Lund University, Lund, Sweden, ⁴¹Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁴²Federal University of Parana, CURITIBA / PR, Brazil, ⁴³Saint Mary Hospital, Bucharest, Romania, ⁴⁴Prof Dr Simona Rednic, Cluj, Romania, ⁴⁵National Kapodistrian University of Athens Medical School, Athens, Greece, ⁴⁶Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, ⁴⁷Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ⁴⁸Rutgers-RWJ Medical School, South Plainfield, NJ, ⁴⁹Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199, Stuttgart, Germany, ⁵⁰Marche Polytechnic University, Ancona, Italy, ⁵¹Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, ⁵²University Hospital Tuebingen, Tuebingen, Germany, ⁵³Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium, ⁵⁴University of Manchester, Salford, United Kingdom, ⁵⁵Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy
Background/Purpose: Systemic sclerosis (SSc) associated pre-capillary pulmonary hypertension (precapPH) is a severe condition that requires prompt treatment. Although immunosuppressants (IMS) are standard of care for…
Abstract Number: 2362 • ACR Convergence 2023
Identification of Protein Biomarkers Associated with the Severity and Risk of Progression of Interstitial Lung Disease in VEDOSS and Established Systemic Sclerosis Patients
Thierry Sornasse¹, Vishal Kakkar², Rebecca Ross³, Sunhwa Kim⁴ and Francesco Del Galdo⁵, ¹AbbVie, Inc., North Chicago, IL, ²University of Leeds, Leeds, United Kingdom, ³Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁴AbbVie, Inc., South San Francisco, CA, ⁵University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Pulmonary Fibrosis (PF) is one of the primary causes of systemic sclerosis (SSc)-related death. Hence, monitoring and predicting the course of PF in SSc…
Abstract Number: 0615 • ACR Convergence 2023
Prevalence of Barrett’s Esophagus in Patients with Systemic Sclerosis
FNU Rida Ul Jannat¹, Devanshu Verma¹ and Laila Sakkal², ¹West Virginia University Hospital, Morgantown, WV, ²West Virginia University, Morgantown, WV
Background/Purpose: Gastrointestinal manifestations of systemic sclerosis are common and include luminal dysmotility. Esophageal aperistalsis (scleroderma esophagus) presents with dysphagia and reflux; and can predispose patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.